Monsanto Concealed Risks Of Non-Hodgkin’s Lymphoma from Roundup, Lawsuit Alleges

A Mississippi man who developed non-Hodgkins lymphoma following years of Roundup use alleges that he may have avoided the cancer diagnosis if Monsanto had not withheld important information about the risks associated with exposure to their controversial weed killer.

In a complaint (PDF) filed last month in the U.S. District Court for the Eastern District of Missouri, Harry C. Sharp indicates that through affirmative misrepresentations and omissions, Monsanto concealed Roundup non-Hodgkins lymphoma risks from consumers.

Sharp begin using Roundup in about 1976, spraying the glyphosate-based herbicide on a regular basis. Although he followed all safety and precautionary warnings, Sharp maintains that he was unaware, and could not have learned through reasonable diligence, that contact with Roundup may cause him to develop non-Hodgkins lymphoma (NHL).

Roundup-Cancer-Lawsuit-Lawyer
Roundup-Cancer-Lawsuit-Lawyer

“Despite Defendantโ€™s knowledge that Roundup was associated with an elevated risk of developing cancer, Defendantโ€™s promotional campaigns focused on Roundupโ€™s purported ‘safety profile’,โ€ Sharp’s lawsuit states. “Defendantโ€™s failure to adequately warn Plaintiff resulted in (1) Plaintiff using and being exposed to glyphosate instead of using another acceptable and safe method of controlling unwanted weeds and pests; and (2) scientists and physicians failing to warn and instruct consumers about the risk of cancer, including NHL, and other injuries associated with Roundup.”

The case joins hundreds of similarย Roundup lawsuitsย brought on behalf of individuals nationwide in recent years, each raising similar allegations that the weed killer and itโ€™s active ingredient, glyphosate, resulted in a diagnosis of non-Hodgkins lymphoma or another cancer.

Concerns about the link betweenย Roundup and cancerย first gained widespread recognition in 2015, when the World Health Organizationโ€™s International Agency for Research on Cancer (IARC) classified glyphosate contained in the weedkiller as a probable human carcinogen. However, Monsanto has continued to dismiss the findings, maintaining that their weedkiller is safe and does not cause cancer.

A growing body of independent research has raised concerns about why Monsanto has failed to provide warnings and recommend safety precautions for users of Roundup, which may have reduced contact with the weedkiller and the risk of non-Hodgkins lymphoma.

As part of the on-going litigation, internal Monsanto documents produced during the discovery process have suggested that the manufacturer knew about the cancer risks associated with Roundup active ingredients for years.

Given similar questions of fact and law raised by individuals nationwide, the federal cases are consolidated as part of a multidistrict litigation (MDL) before U.S. District Judge Vince Chhabria in the Northern District of California, where the pretrial proceedings have been bifurcated, first addressing general causation about the link between Roundup and non-Hodgkins lymphoma, before addressing case-specific issues about whether the weedkiller caused each individual plaintiffs’ diagnosis.

Following resolution of any motions to dismiss based on general causation, if aย Roundup settlementsย or another resolution for the litigation is not reached during the first phase of discovery, it is expected that Judge Chhabria will establish a bellwether process, where a small group of cases will be prepared for early trial dates to help gauge how juries may respond to certain evidence and testimony that is likely to be repeated throughout the lawsuits.

Irvin Jackson
Written by: Irvin Jackson

Senior Legal Journalist & Contributing Editor

Irvin Jackson is a senior investigative reporter at AboutLawsuits.com with more than 30 years of experience covering mass tort litigation, environmental policy, and consumer safety. He previously served as Associate Editor at Inside the EPA and contributes original reporting on product liability lawsuits, regulatory failures, and nationwide litigation trends.




1 Comments


ralph a
Every sentence has been debated several times and Chhabria is not a listener and a pay attentioner so your words are not considered , so a comment about what specific question is requested ?

This field is for validation purposes and should be left unchanged.

Share Your Comments

This field is hidden when viewing the form
I authorize the above comments be posted on this page
Post Comment
Weekly Digest Opt-In

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

MORE TOP STORIES

Lawsuit alleges Olympus failed to address known problems with sterilizing duodenoscopes, leading to a fatal ERCP infection years after federal regulators first raised concerns about the devices.
Federal regulators have centralized at least 23 Boston Scientific spinal cord stimulator lawsuits in a multidistrict litigation that excludes multiple similar claims involving Abbott and Nevro implants.